Gateway Analytical has added new analytical testing and consulting services for OINDPs, the company has announced. New services include identification and particle size distribution (PSD) analysis of agglomerated materials and assessment of agglomerates’ effect on PSD measurements. Gateway already offers ingredient specific particle sizing and other tests for MDIs, DPIs, inhalation solutions, and nasal spray suspensions.
Gateway Senior VP David Exline commented, “We are excited to provide our clients with our expanded analytical testing services that traditionally have only been available in an R&D laboratory setting. The novel techniques utilized in these services will prove to be a cost effective and efficient means of testing in a mainstream laboratory setting for all stages of the drug product development life cycle.”
The company supports product development and FDA submissions for all types of OINDPs, both innovative and generic.
Read the Gateway press release.
